CORDIS
EU research results

CORDIS

English EN
Glioma Actively Personalized Vaccine Consortium

Glioma Actively Personalized Vaccine Consortium

Objective

"Glioblastoma (GBM) is a rare (2-3 incidences in 100,000) and fatal disease. Each year, approximately 13,000 new cases of GBM are diagnosed in Europe. The 5-year survival rate of this highly aggressive tumor entity under conventional therapy is less than 6%. Currently available therapeutic options neglect the individuality of each patients’ disease and only temporarily influence tumor progression with poor effect on overall survival. Introduction of novel highly innovative personalized approaches would have tremendous impacts for the life course of affected patients without additive toxicities. Active cancer immunotherapy aims to trigger the patients´ immune system, specifically cytotoxic T lymphocytes (CTLs) and T helper cells, to defend the body against the cancerous disease. The Glioma Actively Personalized Vaccine Consortium (GAPVAC) aims to conduct a highly innovative pioneering project with active personalized immunotherapy to improve patient treatment. In a Phase I/II study at the center of this proposal, glioblastoma patients will receive a fully personalized peptide-based vaccine as a result of full-genome sequencing and complete peptidomics analysis of the patient’s tumor. Thus, the latest developments in next-generation sequencing, proteomics, immunology, biomarker research and small-scale GMP peptide manufacturing will be uniquely combined to deliver the next generation of personalized medicine to cancer patients. GAPVAC’s goal is to test safety, feasibility and efficacy (biological and early clinical) of this totally novel, completely personalized approach of immunotherapy. GAPVAC is therefore specifically answering the call HEALTH.2012.1.2-1 Development of technologies with a view to patient group stratification for personalized medicine applications by a 4 years project."
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

IMMATICS BIOTECHNOLOGIES GMBH

Address

Paul Ehrlich Str 15
72076 Tuebingen

Germany

Activity type

Other

EU Contribution

€ 1 588 636

Administrative Contact

Mark Bleckmann (Mr.)

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 1 108,34

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 246 108

BIONTECH AG

Germany

EU Contribution

€ 1 143 277

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 908 858,40

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 231 108

UNIVERSITATSKLINIKUM HEIDELBERG

Germany

EU Contribution

€ 251 107,20

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

Israel

EU Contribution

€ 303 750

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 297 108

INSTITUT CATALA DE LA SALUT

Spain

EU Contribution

€ 231 108

UNIVERSITY OF SOUTHAMPTON

United Kingdom

EU Contribution

€ 231 108

IMMUNOLOGISCHE KREBS-THERAPIE EV

Germany

EU Contribution

€ 37 799

BCN PEPTIDES S.A

Spain

EU Contribution

€ 499 360

Project information

Grant agreement ID: 305061

Status

Closed project

  • Start date

    1 November 2012

  • End date

    31 January 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 918 396

  • EU contribution

    € 5 970 436

Coordinated by:

IMMATICS BIOTECHNOLOGIES GMBH

Germany